Fidaxomicin for Clostridiodes difficile infection in inflammatory bowel disease: a multicenter retrospective cohort study
Inflammatory bowel disease (IBD) patients with Clostridiodes difficile Infection (CDI) are at increased risk of disease exacerbations, therapy escalation, colectomy, and mortality. Data on fidaxomicin use in IBD patients with CDI are very limited. We aimed to assess the effectiveness and safety of fidaxomicin for CDI and its impact on IBD outcomes in a large retrospective multicenter cohort study
Publication Details
- Journal
- Open Repository and Bibliography (University of Liège)
- Published
- 2025-01-01
- Primary Topic
- Clostridium difficile and Clostridium perfringens research
- Type
- article
- Field-Weighted Citation Impact
- 0.00